Aberrant expression of MAPs, such as Tau, MAP2 and MAP4, is associated with the resistance phenotype of microtubule-targeting chemotherapy in various tumors, such as breast cancer, oral squamous cell carcinoma and malignant melanomas [18]. This evidence concerns the gene C3orf62 and breast cancer.